#1 Clinical Trials Search in Europe

Gremubamab

A new clinical trial is underway to evaluate the effectiveness of Gremubamab, a potential treatment for patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. This phase 2 trial aims to compare Gremubamab with a placebo to assess its impact on bacterial burden, quality of life, and lung function in affected individuals. The study, known as the GRemubamab ErAdication Trial (GREAT-2), offers hope for those struggling with this challenging respiratory condition.

Table of Contents

What is Gremubamab?

Gremubamab, also known by its sponsor product code MEDI3902, is a new medication being studied for the treatment of certain respiratory conditions[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety. Gremubamab is classified as a protein-based medication, which means it’s derived from or designed to mimic natural proteins in the body[1].

Medical Conditions Treated

Gremubamab is being investigated primarily for the treatment of bronchiectasis with chronic Pseudomonas aeruginosa infection[1]. Let’s break down these terms:

  • Bronchiectasis: This is a condition where the airways in the lungs become abnormally widened, leading to a build-up of excess mucus. This can cause breathing difficulties and repeated lung infections.
  • Pseudomonas aeruginosa: This is a type of bacteria that can cause severe lung infections, especially in people with weakened immune systems or lung conditions like bronchiectasis.
  • Chronic infection: This means the infection is long-lasting or keeps recurring.

The clinical trial is specifically looking at two types of bronchiectasis[1]:

  1. Non-cystic fibrosis bronchiectasis: This is bronchiectasis that is not caused by cystic fibrosis, a genetic disorder.
  2. Tuberculous bronchiectasis: This is bronchiectasis caused by tuberculosis, where tubercle bacilli (TB bacteria) are found in the sputum.

How Gremubamab Works

While the exact mechanism of action is not detailed in the provided information, Gremubamab is designed to target Pseudomonas aeruginosa bacteria in the lungs[1]. The main objective of the treatment is to reduce the amount of these bacteria in the sputum (the mixture of saliva and mucus coughed up from the respiratory tract).

Clinical Trial Details

The clinical trial for Gremubamab, known as the “GRemubamab ErAdication Trial (GREAT-2),” is a Phase 2 study[1]. Here are some key details about the trial:

  • It’s a randomized, placebo-controlled trial, which means some participants will receive Gremubamab while others will receive a placebo (a substance with no active medication).
  • The trial is “blinded,” meaning neither the participants nor most of the research staff know who is receiving the actual medication.
  • The study will last for 168 days (about 24 weeks), with various assessments done throughout this period.

Eligibility Criteria

To participate in the Gremubamab trial, patients must meet certain criteria[1]. Some key inclusion criteria are:

  • Having a clinical diagnosis of bronchiectasis
  • Evidence of bronchiectasis on a CT scan
  • Presence of P. aeruginosa in sputum or other airway samples

There are also several exclusion criteria, including:

  • Known hypersensitivity to Gremubamab
  • Primary diagnosis of chronic obstructive pulmonary disease (COPD) or poorly controlled asthma
  • Severe lung function impairment
  • Certain other medical conditions or treatments that might interfere with the study

Potential Benefits

The researchers hope that Gremubamab will provide several benefits for patients[1]:

  • Reduction in the amount of P. aeruginosa bacteria in the lungs
  • Possible eradication of P. aeruginosa in some individuals
  • Improvement in health-related quality of life
  • Delay in the time to the next exacerbation (worsening) of bronchiectasis
  • Improvement in lung function

Administration and Dosage

Gremubamab is administered as an intravenous infusion, which means it’s given directly into a vein[1]. The medication is diluted in saline to a total volume of 250 mL. The trial is testing two different doses:

  • 1500 mg
  • 500 mg

The treatment is given over a period of 12 weeks, with a maximum total dose of 4500 mg over this time.

Safety Considerations

As with any new medication, safety is a crucial aspect of the Gremubamab trial[1]. The researchers will be closely monitoring participants for any side effects or adverse reactions throughout the study period. It’s important to note that as this is a Phase 2 trial, the full safety profile of Gremubamab is still being established.

Patients considering participating in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare provider.

Aspect Details
Trial Name GRemubamab ErAdication Trial (GREAT-2)
Drug Tested Gremubamab
Condition Bronchiectasis with chronic Pseudomonas aeruginosa infection
Trial Phase Phase 2
Main Objective Evaluate efficacy of Gremubamab on P. aeruginosa bacterial burden in sputum at week 12
Secondary Objectives Assess effects on quality of life, time to first exacerbation, pulmonary function, safety, and pharmacokinetics
Administration Intravenous infusion (500 mg or 1500 mg)
Trial Duration 24 weeks (12 weeks treatment, 12 weeks follow-up)
Key Inclusion Criteria Diagnosed bronchiectasis, P. aeruginosa in sputum within 24 months
Key Exclusion Criteria Hypersensitivity to Gremubamab, certain comorbidities, recent antibiotic use

FAQ

  • What is Gremubamab and what is it being tested for? Gremubamab is a new drug being tested in a clinical trial for patients with bronchiectasis who have a chronic Pseudomonas aeruginosa infection. The trial aims to see if Gremubamab can reduce the amount of bacteria in the lungs and improve symptoms.
  • How is Gremubamab given to patients in the trial? In the trial, Gremubamab is given as an intravenous infusion. This means it's delivered directly into the bloodstream through a vein. The drug is diluted in a solution and given in doses of either 500 mg or 1500 mg.
  • How long does the trial last? The trial lasts for 24 weeks (about 6 months). The main assessment of the drug's effectiveness is done at week 12, but patients are followed up until week 24 to see if there are any lasting effects after stopping the treatment.
  • What are the main goals of the Gremubamab trial? The main goals are to see if Gremubamab can reduce the amount of Pseudomonas aeruginosa bacteria in the lungs, improve quality of life, delay the time until the next lung infection flare-up, and improve lung function. The trial also aims to check if the drug is safe for patients with bronchiectasis.
  • Who can participate in the Gremubamab trial? The trial is for adults with a confirmed diagnosis of bronchiectasis who have had Pseudomonas aeruginosa in their sputum or airway samples within the past 24 months. However, there are several exclusion criteria, such as having certain other lung conditions or being on specific treatments, which might prevent some people from participating.

Ongoing Clinical Trials on Gremubamab

  • Study on Gremubamab for Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa Infection

    Not recruiting

    1
    Investigated drugs:
    Spain

Glossary

  • Bronchiectasis: A long-term condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection.
  • Pseudomonas aeruginosa: A type of bacteria that can cause lung infections, especially in people with bronchiectasis. It can be difficult to treat because it's often resistant to many antibiotics.
  • Sputum: The mixture of saliva and mucus coughed up from the respiratory tract, often examined in respiratory conditions to check for infection.
  • Placebo: A substance that has no active ingredients and no therapeutic effect, used in clinical trials to compare with the actual drug being tested.
  • Intravenous infusion: A method of delivering medications directly into a vein over a period of time.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that shows how much air a person can forcefully exhale in one second.
  • Exacerbation: A worsening of symptoms or a flare-up in a chronic disease, often referring to increased respiratory symptoms in lung conditions.
  • Eradication: In this context, it refers to completely removing or eliminating the Pseudomonas aeruginosa bacteria from the lungs.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Computerised tomography (CT) scan: A type of imaging test that uses X-rays and a computer to create detailed images of the inside of the body, used in this trial to confirm bronchiectasis.

References

  1. http://clinicaltrials.eu/trial/study-on-gremubamab-for-patients-with-bronchiectasis-and-chronic-pseudomonas-aeruginosa-infection/